Cloverleaf Bio

Cloverleaf Bio has designed and engineered "trojan horse tRNAs" that can inhibit over 25 tRNA-modifying enzymes, aiming to create highly potent and targeted cancer therapeutics, beginning with hepatocellular carcinoma (HCC). The venture’s innovation enhances therapeutic efficacy in addition to reducing the likelihood of resistance, which is currently commonly developed by cancer patients within 1-2 years of treatment. Their key differentiation lies in the use of a single tRNA-based molecule to target multiple enzymes simultaneously, offering a more comprehensive and effective approach compared to traditional single target small molecule therapies.